Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
NCT07702032Phase 3Recruiting
- Lead sponsor
- Genmab (Industry)
- Enrollment
- 960 (estimated)
- Start date
- 11 Aug 2026
- Primary completion
- Jul 2029 (estimated)
- Study completion
- 1 Sep 2031
- Last update posted
- 6 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 2
Interventions
- Petosemtamab Drug
- Cetuximab Drug
- FOLFIRI Drug
- mFOLFOX6 Drug
Conditions and primary outcome
- Left-sided Colorectal Cancer
Primary outcome
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 35 months); Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICR (Up to approximately 35 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07702032.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07702032 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.